ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
23 Januar 2019 - 7:35AM
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage
biopharmaceutical company targeting cancers that are both highly
prevalent in Asia and orphan indications in the United States and
Europe, today announced that new pre-clinical data on varlitinib’s
activity in triple negative breast cancer (TNBC) cell lines have
been published online in Cancers, a peer-reviewed oncology journal.
The data suggest that HER-family signalling plays an important role
in TNBC progression and that pan-HER inhibition is potentially an
effective treatment for TNBC patients.
The article titled “Varlitinib Downregulates HER/ERK Signaling
and Induces Apoptosis in Triple Negative Breast Cancer Cells”
details the findings of the pre-clinical study in which
investigators evaluated the efficacy of varlitinib, a reversible
small molecule pan-HER inhibitor, in TNBC. In addition to data
previously presented at the American Association for Cancer
Research in 2017, the data show that varlitinib inhibited cell
proliferation of three further TNBC cell lines.
TNBC is a complex disease associated with an aggressive
phenotype and poor prognosis, and there are currently no approved
therapies for the majority of TNBC patients. TNBC lacks HER2
expression, however it has been reported that other HER receptors
are overexpressed. The data from the study show that varlitinib
inhibited HER signalling in TNBC cell lines of multiple subtypes
(basal-like, mesenchymal-like and luminal androgen receptor) which
induced cell apoptosis and reduced cell viability. Varlitinib
inhibited pHER3 and pHER4 activation, in addition to pEGFR, in
varlitinib-sensitive MDA-MB-468 TNBC cells and suppressed tumour
growth in a MDA-MB-468 xenograft mouse model. In one
varlitinib-resistant TNBC cell line (MDA-MB-231), varlitinib in
combination with either a MEK or ERK inhibitor induced cell
apoptosis.
ASLAN has previously reported positive data from a clinical
study of varlitinib in patients with HER2 positive metastatic
breast cancer. The company is currently investigating varlitinib in
global studies in biliary tract cancer.
Dr Mark McHale, Chief Operating Officer, ASLAN
Pharmaceuticals, said: “We’re pleased to note the
publication of these new data in an authoritative cancer research
journal. The data provides further evidence of varlitinib’s
efficacy as a pan-HER inhibitor as we continue to study its ability
to inhibit tumour growth in biliary tract cancer in the clinic, an
indication associated with high HER family expression.”
The publication is available to view via
https://www.mdpi.com/2072-6694/11/1/105.
Ends
Media and IR contacts
Emma
ThompsonSpurwing CommunicationsTel: +65 6340 7287Email:
ASLAN@spurwingcomms.com |
Robert
UhlWestwicke PartnersTel: +1 858 356 5932Email:
robert.uhl@westwicke.com |
About varlitinib (ASLAN001) Varlitinib
(ASLAN001) is a highly potent, oral, reversible, small molecule
pan-HER inhibitor that targets the human epidermal growth factor
receptors HER1, HER2 and HER4. These receptors can be mutated or
overexpressed in many tumours, which can cause excessive
proliferative activity and uncontrolled growth. Therefore, by
inhibiting the activation of the HER receptors, varlitinib could
inhibit proliferation and control tumour growth. Varlitinib is
currently being studied in biliary tract, breast and colorectal
cancers. Varlitinib has been granted orphan drug designation in the
United States for cholangiocarcinoma, a sub-type of biliary tract
cancer, and was awarded orphan drug designation for the treatment
of biliary tract cancer by the Ministry of Food and Drug Safety in
South Korea.
About ASLAN Pharmaceuticals ASLAN
Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage
oncology-focused biopharmaceutical company developing novel
therapeutics for global markets. ASLAN targets diseases that are
both highly prevalent in Asia and orphan indications in the United
States and Europe. Led by a senior management team with extensive
experience in global and regional development and
commercialisation, ASLAN is headquartered in Singapore and has
offices in Taiwan and China. ASLAN’s portfolio is comprised of four
product candidates which target validated growth pathways applied
to new patient segments, novel immune checkpoints and novel cancer
metabolic pathways. ASLAN’s partners include Array BioPharma,
Bristol-Myers Squibb, Almirall and CSL. For additional information
please visit www.aslanpharma.com.
Forward looking statementsThis release and the
accompanying financial information, if any, contains
forward-looking statements. These statements are based on the
current beliefs and expectations of the management of ASLAN
Pharmaceuticals Limited and/or its affiliates (the "Company").
These forward-looking statements may include, but are not limited
to, statements regarding the Company’s business strategy, the
Company’s plans to develop and commercialise its product
candidates, the safety and efficacy of the Company’s product
candidates, the Company’s plans and expected timing with respect to
regulatory filings and approvals, and the size and growth potential
of the markets for the Company’s product candidates. The Company’s
estimates, projections and other forward-looking statements are
based on management's current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and
inherently involve significant known and unknown risks and
uncertainties. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation the risk factors described in the
Company’s US Securities and Exchange Commission filings and reports
(Commission File No. 001-38475), including the Company’s prospectus
dated May 8, 2018 filed with the US Securities and Exchange
Commission on such date.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024